Long-term Prognosis of Paroxysmal Atrial Fibrillation and Predictors for Progression to Persistnt or Chronic Atrial Fibrillation in the Korean Population
Abstract:Little is known about the long-term prognosis of or predictors for the different clinical types of atrial fibrillation (AF) in Korean populations. The aim of this study was to validate a risk stratification to assess the probability of AF progression from paroxysmal AF (PAF) to persistent AF (PeAF) or permanent AF. A total of 434 patients with PAF were consecutively enrolled (mean age; 71.7 ± 10.7 yr, 60.6% male). PeAF was defined as episodes that are sustained > 7 days and not self-terminating, while permanen… Show more
“…During the follow-up period, the onset of persistent AF was defined as the first time in which all ECGs indicated AF after !3 consecutive ECGs at intervals of !1 week after the initial observation. Permanent AF was defined as AF that was present for at least 6 months without intervening spontaneous episodes of sinus rhythm for which cardioversion was unsuccessful and subsequently not attempted [19,20]. When an ECG could not be obtained 3 times during the period, physicians made a clinical decision regarding the onset time of AF progression.…”
Section: Definitions and Outcomesmentioning
confidence: 99%
“…When an ECG could not be obtained 3 times during the period, physicians made a clinical decision regarding the onset time of AF progression. When electrical cardioversion was performed after >7 days from AF onset, it was considered AF progression [20].…”
“…During the follow-up period, the onset of persistent AF was defined as the first time in which all ECGs indicated AF after !3 consecutive ECGs at intervals of !1 week after the initial observation. Permanent AF was defined as AF that was present for at least 6 months without intervening spontaneous episodes of sinus rhythm for which cardioversion was unsuccessful and subsequently not attempted [19,20]. When an ECG could not be obtained 3 times during the period, physicians made a clinical decision regarding the onset time of AF progression.…”
Section: Definitions and Outcomesmentioning
confidence: 99%
“…When an ECG could not be obtained 3 times during the period, physicians made a clinical decision regarding the onset time of AF progression. When electrical cardioversion was performed after >7 days from AF onset, it was considered AF progression [20].…”
“…Появление систолической дисфункции ЛЖ определяет быстрое прогрессирование ФП у больных ХСН. [19]. LVH and increased arterial stiffness, revealed in our study, testify to target organ damage in HT and promote the cardiovascular system remodeling by the way of the early vascular aging syndrome and the hypertensive heart disease development.…”
Section: Discussionmentioning
confidence: 55%
“…Im и соавт. основными факторами прогрессирования аритмии были названы: возраст старше 75 лет, наличие предсердной аритмии на протяжении всего периода наблюдения, высокий индекс массы тела, низкая ФВ ЛЖ, наличие ГЛЖ и выраженная митральная регургитация [19].…”
Aim. To identify predictors of progression of atrial fibrillation (AF) in patients with hypertension (HT), coronary heart disease (CHD) and chronic heart failure (CHF) with recurrent AF. Material and methods. The study included 312 patients with recurrent AF. The patients were divided into 3 groups according to a leading underlying condition: essential HT (n=136), CHD (n=112), and CHF with III-IV functional class by NYHA (n=64). The average follow-up duration was 60±3 months. Progression of AF was defined as development of long-standing persistent or permanent AF. Results. All three groups of patients with recurrent AF revealed progression of the arrhythmia from paroxysmal or persistent to a sustained permanent form during the 5-year prospective follow-up. The rate of AF progression in the patients with CHF was significantly higher and accounted for 59% as compared to 46% in the patients with hypertension (p=0.002) and 51% in the patients with CHD (p=0.008). AF progression in patients with HT correlated significantly with left ventricular (LV) hypertrophy (odds ratio [OR] 1.25; 95% confidence interval [95%CI] 1.03-1.52) and increased arterial wall stiffness (OR 2.3; 95%CI 1.95-2.65). The independent predictors of arrhythmia progression in patients with CHD were a history of myocardial infarction (OR 1.23; 95%CI 0.9-1.5), irreversible LV wall motion abnormalities (OR 1.41; 95%CI 1.1-1.7), and increased plasma level of N-terminal pro-A-type natriuretic peptide (Nt-proANP; OR 1.16; 95%CI 0.8-1.4). Reduction in LV ejection fraction below 40% (OR 0.84; 95%CI 0.7-0.89) and increased plasma N-terminal pro-B-type natriuretic peptide (Nt-proBNP; OR 2.3; 95%CI 1.93-2.67) were independent predictors of AF progression from persistent to permanent form in the patients with systolic heart failure. Conclusion. Progression of AF is related to the underlying cardiovascular disease. The early vascular aging syndrome and LV hypertrophy are the main factors of AF progression in patients with HT. Previous myocardial infarction with irreversible hypokinesia is associated with AF progression in patients with CHD. Reduced LV ejection fraction and increased plasma BNP predict AF progression in patients with CHF.
“…Patients suffering from paroxysmal AF progress to more frequent and long-lasting episodes and into persistent and permanent stages. Numerous recordings have documented that this progression is associated not only with the evolution time [6][7][8][9] but also with the existence of other comorbidities as indicated by the HATCH score [10,11]. This evolution occurs along with structural changes at the atrial level that include chamber dilatation and substitution of the myocardial tissue with fibrotic tissue that causes the situation to be irreversible [12].…”
Key Clinical MessageIn patients with permanent atrial fibrillation (AF) and implantable cardioverter–defibrillator (ICD) implant indication, a single‐chamber device is the choice because AF does not provide interesting information for the treatment. It is very unusual to find patients with permanent AF that coexist with atrial tachycardia with various degree of Atrioventricular block.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.